Key facts
- This page summarizes Ansbert Gadicke's Form 4 filing for TCR2 THERAPEUTICS INC..
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 05 Jun 2023, 16:35.
Ansbert Gadicke - 01 Jun 2023 Form 4 Insider Report for TCR2 THERAPEUTICS INC.
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 01 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Jun 2023, 16:35:42 UTC
- Prior SEC filing
- 24 May 2023
- Next SEC filing
- 30 Apr 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ansbert Gadicke
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ansbert Gadicke filed Form 4 for TCR2 THERAPEUTICS INC. on 05 Jun 2023.
Change
- Previous filing in this sequence was filed on 24 May 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TCRR
transaction
Common Stock
Other
- Transaction value
- $0
- Shares
- -304,001
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Jun 2023
- Ownership
- See Footnote
- Footnotes
- F1, F2, F3
TCRR
transaction
Common Stock
Other
- Transaction value
- $0
- Shares
- -3,854,963
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Jun 2023
- Ownership
- See Footnote
- Footnotes
- F1, F2, F4
TCRR
transaction
Common Stock
Other
- Transaction value
- $0
- Shares
- -3,370,982
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Jun 2023
- Ownership
- See Footnote
- Footnotes
- F1, F2, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Ansbert Gadicke is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 5 footnotes
Footnote F1
This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").
Footnote F2
At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares").
Footnote F3
The shares were held by MPM Asset Management LLC ("AM LLC"). The reporting person is a member of AM LLC and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Footnote F4
The shares were held as follows: 3,056,272 by MPM BioVentures 2014, L.P. ("BV 2014"), 203,846 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 110,859 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 421,070 by MPM SunStates Fund, L.P. ("MPM SunStates") and 62,916 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B) and BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates and SunStates GP is the manager of AM SunStates. The reporting person is a managing director of BV LLC and a member of SunStates GP and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Footnote F5
The shares were held by UBS Oncology Impact Fund L.P. ("UBS Oncology"). BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. The reporting person is the managing partner of BioImpact and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.